{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218142","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-05-12T11:05:16+00:00","discovered_at":"2026-05-12T11:10:00.362945+00:00","generated_at":"2026-05-12T11:13:46.039323+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026","bullets":["Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.","Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.","GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.","Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.","Initial Phase 1 data for OP-3136 to be presented at ASCO 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218142","json":"https://secwatch.observer/filing/0001193125-26-218142.json","markdown":"https://secwatch.observer/filing/0001193125-26-218142.md","text":"https://secwatch.observer/filing/0001193125-26-218142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/0001193125-26-218142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/olma-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:13:46.039323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"268b4250bb1a31f69e448104f4283da42ed64d3b","claim":"Olema Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc.","evidence_excerpt":"On May 12, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/0001193125-26-218142-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}